Gyre Therapeutics (GYRE) Non-Current Assets (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Non-Current Assets of $70.3 million for Q1 2026, up 14.58% year-over-year from $61.3 million in Q1 2025, and up 10.23% quarter-over-quarter from $63.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Non-Current Assets (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non-Current Assets for 17 consecutive years, with $70.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 14.58% year-over-year to $70.3 million; the TTM figure through Mar 2026 stood at $256.2 million (down 1.38% YoY), while the FY2025 annual figure was $63.8 million, up 5.18% from the prior year.
- Non-Current Assets advanced to $70.3 million in Q1 2026 per GYRE's latest filing, from $63.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $70.4 million in Q3 2024 and bottomed at $773000.0 in Q3 2022.
- Historically, Non-Current Assets has averaged $40.6 million across 5 years, with a median of $59.3 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 83.1% — and 2024, when it jumped 1357.6%.
- Gyre Therapeutics' Non-Current Assets stood at $35.1 million in 2022, then surged by 69.0% to $59.3 million in 2023, then rose by 2.19% to $60.6 million in 2024, then climbed by 5.18% to $63.8 million in 2025, then climbed by 10.23% to $70.3 million in 2026.
- Business Quant data shows GYRE's Non-Current Assets at $70.3 million in Q1 2026, $63.8 million in Q4 2025, and $60.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 77.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.18 Mn |
| Mar 31, 2026 | 70.28 Mn |
| Dec 31, 2025 | 63.76 Mn |
| Sep 30, 2025 | 60.81 Mn |
| Jun 30, 2025 | 61.36 Mn |
| Mar 31, 2025 | 61.34 Mn |
| Dec 31, 2024 | 60.62 Mn |
| Sep 30, 2024 | 70.43 Mn |
| Jun 30, 2024 | 67.41 Mn |
| Mar 31, 2024 | 59.29 Mn |
| Dec 31, 2023 | 59.32 Mn |
| Sep 30, 2023 | 4.83 Mn |
| Jun 30, 2023 | 4.77 Mn |
| Mar 31, 2023 | 4.74 Mn |
| Dec 31, 2022 | 35.10 Mn |
| Sep 30, 2022 | 773,000.00 |
| Jun 30, 2022 | 2.07 Mn |
| Mar 31, 2022 | 3.57 Mn |
| Dec 31, 2021 | 4.19 Mn |
| Sep 30, 2021 | 4.57 Mn |